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Abstract. Polycationic cell-penetrating peptides (CPPs) deliver 
macromolecules into cells without losing the functional prop-
erties of the cargoed macromolecule. The aim of this study 
was to determine whether exogenous cytochrome c is delivered 
to HeLa cervical carcinoma cells by the CPP antennapedia 
(Antp) and activates apoptosis. HeLa cervical carcinoma cells 
were treated with conjugated Antp-SMCC-cytochrome c 
(cytochrome c chemically conjugated to Antp) or with 
non-conjugated Antp and cytochrome c. Sensitivity to the 
treatments was determined by the clonogenic assay (prolifera-
tion) and by immunoblot analysis (apoptosis activation). We 
report that conjugated Antp-SMCC-cytochrome c activated 
apoptosis in HeLa cells as demonstrated by poly (ADP-ribose) 
polymerase 1 (PARP-1) cleavage and inhibited their prolifera-
tion. The Antp-SMCC-cytochrome c-induced apoptosis was 
inhibited by z-VAD-fmk, a pan-caspase inhibitor peptide. 
Unconjugated Antp or cytochrome c demonstrated no inhibi-
tory effect on survival and proliferation. Our results suggest 
that chemical coupling of cytochrome c to CPPs may present 
a possible strategy for delivering cytochrome c into cells and 
for activating apoptosis.
Introduction
Cytochrome c is a highly conserved, water-soluble protein 
of 12.3 kD with a net positive charge at neutral pH, residing 
loosely attached in the mitochondrial intermembrane space. 
It has a dual function; it is involved in energy production 
in mitochondria by interaction with redox partners and 
it also has a critical function in the induction of intrinsic 
(cytochrome c/mitochondria-mediated) apoptosis. Intrinsic 
apoptosis is activated by cellular stress originating from inside 
the cell (e.g. DNA damage or the presence of reactive oxygen 
species) and is strictly dependent on the release of cyto-
chrome c from the mitochondria into the cytoplasm upon an 
intrinsic (i.e. of intracellular origin) stimulus. Cytochrome c 
is then, together with other cytosolic factors, including apop-
totic protease activating factor 1 (Apaf-1) and pro-caspase-9, 
assembled into the apoptosome. Following apoptosome 
assembly and activation of pro-caspase-9 (initiator caspase), 
the downstream caspases-3 and -7 (effector caspases) are 
cleaved and thereby activated. This leads to the execution of 
the apoptotic program, culminating in the dismantling of the 
cell (1-4). Apoptosis also occurs through the extrinsic (cyto-
chrome c-independent) Fas/FasL-mediated pathway, which 
merges with the intrinsic pathway at the level of the effector 
caspases-3 and -7 (5).
7KHÀQGLQJVWKDWH[RJHQRXVcytochrome c, either micro-
injected directly into the cytoplasm or delivered into the 
cytoplasm by electroporation, activates apoptosis without 
the requirement for additional apoptotic stimuli supports the 
critical role of cytochrome c in apoptosis (6-8). Related studies 
have demonstrated that apoptosis in tumor cells is activated by 
cytochrome c delivered by nanoparticles, including nanotubes 
or polylactic-co-glycolic acid (PLGA) microspheres (9,10). 
This suggests that the cytoplasmic delivery of exogenous cyto-
chrome c through suitable carriers with subsequent apoptosis 
activation is a potential therapeutical approach against cancer. 
Contrary to necrosis, apoptosis does not induce an immune 
response of the surrounding tissue, which may be of clinical 
VLJQLÀFDQFH
Cell-penetrating peptides (CPPs) are a group of peptides 
that are often ~20 amino acids long and contain a cluster of 
basic residues. Based on their property of translocating across 
the hydrophobic cell membrane, they are also capable of 
delivering protein- and DNA-based macromolecules and drug 
molecules to cells without the loss of biological activity of the 
conveyed materials. CPPs are intensively studied and consid-
ered as important carriers in drug delivery (11-15).
Antennapedia (Antp) is one member of the family of 
CPPs. Antp was originally derived from the 60 amino acid 
long homeodomain of the Drosophila transcription factor 
Antennapedia (16). Later on, its translocation ability was 
narrowed down to a 16-mer, termed as penetratin (Antp 
PTD, 43-58 residues, RQIKIWFQNRRMKWKK) present in 
the homeodomain (17). In the present study we describe the 
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effects of Antp-SMCC-cytochrome c, a conjugate molecule 
synthesized from cytochrome c and Antp on apoptosis activa-
tion and proliferation inhibition in HeLa cervical tumor cells.
Materials and methods
Cell culture and compounds. HeLa cervical cancer cells 
(obtained from Dr G. Marra, Institute of Molecular Cancer 
Research, University of Zurich) were routinely cultured 
in Iscove's modified Dulbecco's medium (IMDM)-21980 
(Invitrogen, Basel, Switzerland) containing 10% fetal calf 
VHUXP2[RLG%DVHO6ZLW]HUODQGDWÝ&DQGLQDQDWPR-
sphere of 5% carbon dioxide and 95% humidity. Horse heart 
cytochrome c was purchased from Sigma-Aldrich Chemie 
GmbH (Buchs, Switzerland) and a stock solution (20 mg/ml, 
P0ZDVSUHSDUHGLQVWHULOHZDWHUDQGVWRUHGDWÝ&7KH
19-mer synthetically synthesized Antp peptide was purchased 
from Bachem (Bubendorf, Switzerland) and solutions were 
prepared in phosphate-buffered saline (PBS) containing 2 mM 
tributylphosphine prior to use. This Antp peptide (amino acid 
sequence, Ser-Gly-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-
Arg-Arg-Met-Lys-Trp-Lys-Lys-Cys) was biotinylated at 
the 5'-carboxy terminus and functionalized at the 3'-amino 
WHUPLQXVZLWKD WULÁXRURDFHWDWHJURXS6XOIRVXFFLQLPLG\O
4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) 
was purchased from Pierce Biotechnology Inc. (Lausanne, 
Switzerland) and solutions were freshly prepared in PBS. The 
pan-caspase inhibitor peptide z-VAD-fmk was purchased from 
Enzo Life Sciences (Laufen, Switzerland) and a stock solution 
LQGLPHWK\OVXOIR[LGH'062ZDVVWRUHGDWÝ&
Conjugate synthesis. The Antp-SMCC-cytochrome c conju-
gate synthesis was a two-step reaction, where sulfo-SMCC 
was used as a cross-linker molecule (also referred to as a 
bifunctional coupling reagent). The conjugate synthesis was 
performed as follows: In the first step, cytochrome c was 
incubated with crystalline sulfo-SMCC in PBS at a molar 
ratio of protein molecules to succinimidyl groups of 1:4 for 
60 min under continuous stirring at room temperature. This 
coupled the sulfo-SMCC covalently to cytochrome c. Excess 
VXOIR60&&ZDVUHPRYHGE\RYHUQLJKWGLDO\VLVDWÝ&DJDLQVW
PBS. In the second step, the sulfo-SMCC-coupled cytochrome c 
was incubated with freshly prepared Antp solution containing 
2 mM tributylphosphine (to prevent dimerization of the Antp 
peptides) at a molar ratio of cytochrome c-SMCC:Antp of 1:5 
IRUKXQGHUFRQWLQXRXVVWLUULQJDWÝ&7KHUHGGLVKFRQMX-
gate solution was then filtered [Millex-HV polyvinylidene 
ÁXRULGH39')PSRUHVL]HVWHULOHÀOWHU@7KHFRQFHQ-
tration of cytochrome c in the conjugate was determined by a 
cytochrome c (human) enzyme-linked immunosorbent assay 
(ELISA) kit (Enzo Life Sciences) according to the manufac-
turer's instructions.
Cell lysates and immunoblot analysis. Immunoblot analysis 
was performed in cell lysates to assess apoptosis on the basis 
of the treatment-induced proteolytic cleavage of the 116 kDa 
PARP-1 precursor into its 89 kDa fragment. Proteolytic PARP-1 
cleavage is an acknowledged measure of ongoing apoptosis. 
Cell lysates were produced from untreated HeLa control 
cultures or HeLa cultures treated with either the Antp-SMCC-
cytochrome c conjugate or the non-conjugated compounds 
(cytochrome c, Antp) for 24 h, washed in PBS and lysed 
according to standard laboratory protocols. In certain cultures 
the pan-caspase inhibitor peptide z-VAD-fmk was added (10 or 
0KEHIRUHWKHDGGLWLRQRI$QWS60&&cytochrome c. 
The protein concentration of cell lysates was determined 
using the BCA Protein Assay kit (Pierce Biotechnology Inc.). 
For immunoblot analysis (performed following standard 
ODERUDWRU\SURWRFROVJFHOOO\VDWHSURWHLQZDVVHSDUDWHG
using 10% sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE), followed by blotting onto a PVDF 
PHPEUDQH$PHUVKDP%LRVFLHQFHV2WHOÀQJHQ6ZLW]HUODQG
3URWHLQVZHUHGHWHFWHGE\WKHVSHFLÀFSULPDU\DQWLERGLHVDQG
the respective secondary antibodies: horseradish peroxidase 
(HRP)-conjugated anti-mouse (M15345; BD Transduction 
Laboratories, Lexington, KY, USA) or HRP-conjugated anti-
rabbit (7074, Cell Signaling Technology Inc./BioConcept, 
Allschwil, Switzerland). The primary antibodies used were 
PARP-1 (9542, Cell Signaling; recognizing the 116 kDa 
full-length PAPR-1 and the cleaved 89 kDa fragment) and 
anti-mouse ơ-actin (A5441, Sigma) or anti-rabbit Ơ/ơ-tubulin 
(2148, Cell Signaling) as sample loading controls. Complexes 
were visualized by enhanced chemiluminescence (Amersham 
Biosciences) and autoradiography. A HeLa cell culture treated 
with 0.8 mM H2O2 for 6 h served as the positive control sample 
for apoptosis.
Clonogenic assay. The sensitivity of HeLa cells to the treat-
ments was determined by the clonogenic assay. HeLa cells 
(500 cells in 2 ml culture medium) were plated in 35 mm 
cell culture plates. Then, 24 h after plating, the cells were 
treated with various concentrations of either the conjugate 
or the non-conjugated compounds for 24 h. Then, the 
drug-containing medium was replaced with drug-free 
PHGLXP6HYHQGD\VDIWHUWUHDWPHQWFHOOVZHUHÀ[HGZLWK
25% acetic acid in ethanol and stained with Giemsa. Colonies 
RI  FHOOVZHUH VFRUHG YLVXDOO\(DFK H[SHULPHQWZDV
performed three times. Clonogenic survival was presented 
as the percentage of the untreated control as a function of the 
compound concentration.
Results
Antp-SMCC-cytochrome c conjugate activates caspase-
dependent apoptosis. Immunoblot data (Fig. 1A) revealed that, 
in comparison with the untreated control sample, the treat-
ment of HeLa cells with Antp-SMCC-cytochrome c resulted 
in the cleavage of the 116-kDa PARP-1 precursor into an 
89-kDa cleaved fragment (a measure for ongoing apoptosis). A 
concentration of cytochrome c (contained in the conjugate and 
measured by cytochrome cVSHFLÀF(/,6$DVORZDVJ/ml 
ZDVVXIÀFLHQWWRUHVXOW LQ3$53FOHDYDJHLH WRDFWLYDWH
apoptosis. By contrast, PARP-1 cleavage was not observed 
when HeLa cells were treated with either cytochrome c 
RU$QWS DORQH DW FRQFHQWUDWLRQV RI XS WR  JPO RU
J/ml, respectively (Fig. 1B). This indicates that apoptosis 
is activated by treatment with the Antp-SMCC-cytochrome c 
conjugate but not with Antp or cytochrome c alone.
The 2-h pretreatment of HeLa cultures with 10 or 
 0 ]9$'IPN DQG WKH VXEVHTXHQW WUHDWPHQW ZLWK
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Antp-SMCC-cytochrome c  JPO HOLPLQDWHG WKH
Antp-SMCC-cytochrome c-induced apoptosis. This was 
manifested by the failure to detect PARP-1 precursor cleavage 
(Fig. 1C). As a broad spectrum caspase inhibitor peptide, 
z-VAD-fmk irreversibly inhibits the activity of the majority of 
the members of the caspase-family, indicating that the Antp-
SMCC-cytochrome c-induced apoptosis was caspase-dependent.
Antp-SMCC-cytochrome c conjugate inhibits clonogenic 
survival. The Antp-SMCC-cytochrome c conjugate reduced 
the clonogenic survival of Hela cells (Fig. 2A). A concentration 
DVORZDVJPOcytochrome c (contained in the conjugate) 
ZDVVXIÀFLHQWWRFRPSOHWHO\EORFNWKHFORQRJHQLFSRWHQWLDORI
HeLa cells. By contrast, cytochrome cDORQHJPORU
$QWSDORQHJPOGLGQRWSURGXFHDVXEVWDQWLDOQHJD-
tive effect on clonogenic survival (Fig. 2B and C). 
Discussion
Cytochrome c has been shown to activate apoptosis when 
directly microinjected or delivered into tumor cells via elec-
troporation or nanoparticles. CPPs, including Antp, facilitate 
the penetration of various biomolecules and particles into 
cells. On this basis, we synthesized the conjugate molecule 
Antp-SMCC-cytochrome c from the respective compounds 
(cytochrome c and Antp) using the sulfo-SMCC crosslinker 
and determined the effects of this Antp-SMCC-cytochrome c 
conjugate on survival, i.e. apoptosis activation and prolifera-
tion in HeLa cervical cancer cells.
The aim of the present study was to determine whether 
apoptosis in HeLa tumor cells is activated by exogenous 
cytochrome c delivered into the cytoplasm through the CPP 
Antp in the form of a conjugate molecule consisting of Antp 
covalently linked to cytochrome c.
In the current study, we demonstrated that cytochrome c 
covalently conjugated to Antp applied to HeLa cervical 
cancer cell cultures activates caspase-dependent apoptosis 
and inhibits proliferation, whereas neither cytochrome c nor 
Antp alone affected survival and proliferation. Therefore, we 
conclude that the inhibitory effects on survival and prolifera-
tion are attributed to cytochrome c delivered to HeLa cells 
via Antp. This suggests that the Antp-aided delivery of cyto-
chrome c into tumor cells may be a candidate strategy for 
activating apoptosis and consequently inhibiting the survival 
and proliferation of tumor cells.
In a pilot set of experiments, we demonstrated that 
the presence of non-conjugated cytochrome c alone in the 
culture medium did not activate apoptosis nor substantially 
reduce the clonogenic potential at concentrations of up to 
Figure 1. Effects of a 24-h treatment with (A) the Antp-SMCC-cytochrome c 
FRQMXJDWHRUJPODQG%QRQFRQMXJDWHGF\WRFKURPHc (125, 
RU JPO RU QRQFRQMXJDWHG$QWS   RU JPO RQ
apoptosis (i.e. proteolytic cleavage of the 116-kDa PARP-1 precursor into 
a 89-kDa fragment) in HeLa cells. (C) Also shown is the effect of the pan-
FDVSDVHLQKLELWRU]9$'IPNDQG0KSUHWUHDWPHQWRQDSRSWRVLV
(cleavage of the 116 kDa PARP-1 precursor into the 89 kDa fragment) of 
+H/DFHOOVWUHDWHGZLWKJPO$QWS60&&F\WRFKURPHc conjugate for 
24 h. HeLa cells treated with 0.8 mM hydrogen peroxide (H2O2) for 6 h 
served as the positive control sample for apoptosis. Actin and tubulin are 
the sample loading controls. Data are the representatives of two independent 
experiments. Antp, antennapedia; PARP-1, poly (ADP-ribose) polymerase 1.
Figure 2. Effects of a 24-h treatment with (A) the Antp-SMCC-cytochrome c 
conjugate, (B) non-conjugated cytochrome c or (C) non-conjugated Antp on 
the clonogenic survival of HeLa cells. Data points are the mean ± SD of 
three independent experiments performed in triplicate cultures.Antp, anten-
napedia; SD, standard deviation.
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  B
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  B
  C
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J/ml, suggesting that cytochrome c is not accumulated 
LQWKHF\WRSODVP7KLVVXJJHVWLRQLVVXSSRUWHGE\ÀQGLQJVWKDW
cytochrome c is unable to translocate across membranes on its 
own and therefore requires the so-called translocases in the 
outer membrane (TOM) complex for the translocation across 
the mitochondrial outer membrane (18). The presence of 
QRQFRQMXJDWHG$QWSFRQFHQWUDWLRQVJPODORQHLQ
the culture medium had no effect on apoptosis and clonogenic 
potential. This suggests that Antp is not harmful in this experi-
mental setting. It is known that CPPs are toxic to cells due to 
membrane perturbation at higher levels of the peptides (19).
The key finding in the present study was that, unlike 
non-conjugated cytochrome c and Antp, the incubation of HeLa 
cultures with the Antp-SMCC-cytochrome c conjugate resulted 
in the activation of apoptosis and reduction of the clonogenic 
potential of HeLa cells. Antp-SMCC-cytochrome c-induced 
apoptosis is caspase-dependent, since it was inhibited by the 
pan-caspase inhibitor z-VAD-fmk.
The following series of events that eventually lead to apop-
tosis may be proposed on the basis of the results of the current 
study. The Antp-SMCC-cytochrome c conjugate translocates 
across the cellular membrane and accumulates in the cyto-
plasm, where the conjugate is hydrolyzed into its components 
(the SMCC-crosslinker is pH-sensitive). Cytochrome c is then 
DVVHPEOHGLQWRWKHDSRSWRVRPHWKDWLQWXUQÀQDOO\UHVXOWVLQ
the activation and the execution of apoptosis. This implies that 
the structural integrity and the biological function of cyto-
chrome cDUHQRWFRPSURPLVHGE\WKHFKHPLFDOPRGLÀFDWLRQV
made during Antp-SMCC-cytochrome c conjugate synthesis 
and its subsequent hydrolysis. Studies have shown that injection 
of ~10 fg cytochrome cLVVXIÀFLHQWWRDFWLYDWHDSRSWRVLV
corresponding to an estimated intracellular cytochrome c 
FRQFHQWUDWLRQRIa0:KHWKHUDQG WRZKDWH[WHQW
cytochrome c molecules with covalently bound SMCC retain 
functional integrity in terms of proper apoptosome formation 
remains unclear. Likewise, the possible effects of the other 
products of the hydrolysis with respect to apoptosis activation 
and clonogenic survival are unknown, but may be marginal.
It is important to acknowledge that the results of the 
present study should be considered as proof-of-concept only, 
and that more detailed studies should be performed. However, 
hypotheses towards important features related to antitumor 
studies may be proposed.
Conventional chemotherapy is an indispensable therapeutic 
option for the treatment of a number of malignancies. It kills 
tumor cells through the activation of the apoptotic machinery by 
the use of foreign-to-body chemicals or biological compounds. 
7KHVHFRPSRXQGVDUHE\GHÀQLWLRQWR[LFDQGDUHIUHTXHQWO\
of limited bio-tolerability and bio-degradability. Clinicians 
and patients are therefore often confronted with limitations, 
LQFOXGLQJDGYHUVHVLGHHIIHFWSURÀOHVCytochrome c as the 
therapeutically active compound against tumor cells appears 
appealing and may be a candidate alternative to conventional 
chemotherapy. It is intrinsic to cells and not toxic; however, 
it is able to activate apoptosis when delivered to cells from 
outside in femtogram quantities.
Exogenous cytochrome c as the ‘therapeutically’ active 
compound may help overcome certain types of chemotherapy 
resistance. Resistance to chemotherapeutic compounds emerges 
through the expression of multidrug resistance drug efflux 
WUDQVSRUWHUVRUGUXJGHWR[LÀHUVRUWKURXJKWKHHQKDQFHGUHSDLU
of damaged DNA (20). This leads to ineffective mitochondrial 
cytochrome c release due to the absence of apoptotic stimuli, 
to ineffective apoptosome assembly and caspase activation, and 
eventually to ineffective apoptosis execution. Absent release of 
intrinsic cytochrome c may be compensated by the exogenously 
delivered cytochrome c, thereby overcoming chemoresistance. 
It may also be hypothesized that exogenous cytochrome c does 
not cause the acquisition of drug resistance in tumor cells, a 
major problem of conventional chemotherapies.
Despite its intriguing characteristics, there are critical 
issues with the concept of CPP-aided cytochrome c delivery. 
2QHLV WKDW&33VKDYH OLPLWHG WDUJHWVSHFLÀFLW\&33VDUH
likely to deliver their cargo not only to tumor cells, but also to 
normal cells. Further studies are required to render CPP-aided 
GHOLYHU\WDUJHWFHOOVSHFLÀF$QDOWHUQDWLYHWR&33DLGHGF\WRcyto-
chrome c delivery may be cytochrome c delivery via tumor 
cell-targeted immunoliposomes; however, this approach may 
suffer from limitations associated with the intrinsic disad-
vantages of endocytotic-based mechanisms. Another issue is 
what the potential clinical application of the CPP-aided cyto-
chrome c-therapy may be. We performed this study with HeLa 
cervical cancer cells; therefore, it may be applied as a therapy 
of inoperable, local cervical cancers or advanced primary 
inoperable vulvar and vaginal cancers that are easily acces-
sible to, for instance, an Antp-SMCC-cytochome c-containing 
ointment. A similar application may also be suitable for super-
ÀFLDOFDQFHUVLQFOXGLQJVNLQFDQFHU
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